- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.11. | Kelun's MSD-partnered TROP2 drug gets first okay in China | ||
| 29.11. | Bayer opens Berlin incubator and welcomes first resident | ||
| 29.11. | UK government commits to first men's health strategy | ||
| 28.11. | Neuralink unveils trial linking brain implant to robotic arm | ||
| 28.11. | Applied Tx craters as FDA rejects lead product candidate | ||
| 28.11. | FDA probing cancer cases with Bluebird's CALD gene therapy | ||
| 28.11. | Study finds AZ's benralizumab a 'game-changer' in asthma | ||
| 28.11. | Grifols slides as Brookfield pulls out of takeover talks | ||
| 27.11. | Court sides with EU on decision to revoke Ocaliva's license | ||
| 27.11. | Trump puts final piece in his MAHA puzzle with NIH nominee | ||
| 27.11. | Kisqali gets early breast cancer approval in Europe | ||
| 27.11. | Amgen's big reveal of obesity data falls a little flat | ||
| 27.11. | NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy | ||
| 26.11. | Biden ramps up Medicare coverage of obesity drugs | ||
| 26.11. | Medigene axes staff and refocuses its TCR pipeline | ||
| 26.11. | Roche buys off-the-shelf CAR-T player Poseida for $1bn | ||
| 26.11. | MSD adds rocket fuel to Winrevair's engine in PAH | ||
| 26.11. | End looms for Cassava's simufilam in Alzheimer's disease | ||
| 25.11. | Relief for AZ as Truqap hits the spot in prostate cancer | ||
| 25.11. | UK digital health funding should be ringfenced, says report | ||
| 25.11. | Halozyme abandons its €2bn pursuit of Evotec | ||
| 25.11. | Makary confirmed as Trump's FDA pick, with Weldon for CDC | ||
| 25.11. | BridgeBio poised to challenge Pfizer after Attruby approval | ||
| 22.11. | Neurogene drops high-dose arm in Rett study after death | ||
| 22.11. | Neuralink gets okay for its first international trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
